Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zenas BioPharma (ZBIO) Total Liabilities (2023 - 2025)

Zenas BioPharma (ZBIO) has 3 years of Total Liabilities data on record, last reported at $125.6 million in Q3 2025.

  • For Q3 2025, Total Liabilities rose 185.45% year-over-year to $125.6 million; the TTM value through Sep 2025 reached $125.6 million, up 185.45%, while the annual FY2024 figure was $57.5 million, 31.26% up from the prior year.
  • Total Liabilities reached $125.6 million in Q3 2025 per ZBIO's latest filing, up from $53.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $288.8 million in Q2 2024 and bottomed at $43.8 million in Q4 2023.
  • Average Total Liabilities over 3 years is $124.1 million, with a median of $57.5 million recorded in 2024.
  • The widest YoY moves for Total Liabilities: up 185.45% in 2025, down 81.49% in 2025.
  • A 3-year view of Total Liabilities shows it stood at $43.8 million in 2023, then surged by 31.26% to $57.5 million in 2024, then skyrocketed by 118.38% to $125.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Total Liabilities were $125.6 million in Q3 2025, $53.5 million in Q2 2025, and $49.4 million in Q1 2025.